| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
227.84(M) |
| Last
Volume: |
2,211,986 |
Avg
Vol: |
2,301,679 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
86,265 |
122,918 |
235,260 |
541,068 |
| Total Sell Value |
$152,594 |
$177,518 |
$247,417 |
$1,284,611 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
7 |
16 |
37 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kuebler Christopher A |
Director |
– • – |
2017-04-05 |
4 |
AS |
$21.88 |
$328,200 |
D/D |
(15,000) |
35,500 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2017-04-05 |
4 |
OE |
$8.37 |
$125,550 |
D/D |
15,000 |
50,500 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-03-20 |
4 |
AS |
$19.69 |
$2,215,125 |
D/D |
(112,500) |
55,637 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-03-20 |
4 |
OE |
$7.21 |
$1,120,875 |
D/D |
112,500 |
168,137 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2017-03-15 |
4 |
OE |
$8.37 |
$117,180 |
D/D |
14,000 |
98,000 |
|
- |
|
| Chess Robert |
Director |
– • – |
2017-03-14 |
4 |
AS |
$15.41 |
$77,050 |
D/D |
(5,000) |
271,623 |
|
- |
|
| Chess Robert |
Director |
– • – |
2017-03-14 |
4 |
OE |
$8.37 |
$41,850 |
D/D |
5,000 |
276,623 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2017-02-21 |
4 |
AS |
$13.08 |
$392,400 |
D/D |
(30,000) |
30,450 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2017-02-21 |
4 |
OE |
$5.14 |
$154,200 |
D/D |
30,000 |
60,450 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$42,534 |
D/D |
(3,237) |
182,089 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$16,570 |
D/D |
(1,261) |
34,504 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-02-16 |
4 |
S |
$13.14 |
$113,477 |
D/D |
(8,636) |
169,272 |
|
- |
|
| Gergel Ivan |
SVP & Chief Medical Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$19,145 |
D/D |
(1,457) |
45,022 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$30,997 |
D/D |
(2,359) |
69,270 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$25,820 |
D/D |
(1,965) |
55,637 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2017-02-16 |
4 |
S |
$13.14 |
$28,842 |
D/D |
(2,195) |
63,648 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-02-10 |
4 |
OE |
$4.65 |
$209,250 |
D/D |
45,000 |
185,326 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-02-08 |
4 |
AS |
$13.04 |
$1,141,000 |
D/D |
(87,500) |
177,908 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-02-08 |
4 |
OE |
$4.65 |
$406,875 |
D/D |
87,500 |
265,408 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-02-03 |
4 |
S |
$12.48 |
$106,142 |
D/D |
(8,505) |
140,326 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-02-03 |
4 |
OE |
$4.65 |
$39,548 |
D/D |
8,505 |
148,831 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-02-02 |
4 |
S |
$12.38 |
$823,208 |
D/D |
(66,495) |
140,326 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2017-02-02 |
4 |
OE |
$4.65 |
$309,202 |
D/D |
66,495 |
206,821 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-01-17 |
4 |
AS |
$12.35 |
$1,080,625 |
D/D |
(87,500) |
177,908 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2017-01-17 |
4 |
OE |
$4.65 |
$406,875 |
D/D |
87,500 |
265,408 |
|
- |
|
913 Records found
|
|
Page 21 of 37 |
|
|
0.01 (0.79%) 
